tachyarrhythmias or pulmonary hypertension), thereby further impairing cardio-circulatory functions. 3 During the last years, arginine vasopressin and terlipressin have been identified as useful adjunct vasopressors in the treatment of catecholamine-dependent septic shock. 4 -11 Since terlipressin is a pro-drug with a long effective halflife of approximately 6 h, it is usually given as intermittent bolus injection. 8 This approach, however, may contribute to an overshooting increase in systemic vascular resistance and a marked reduction in cardiac index (CI), 12 13 thereby compromising oxygen delivery index (DO 2 I) and mixedvenous oxygen saturation (Sv O 2 ) .
We hypothesized that dobutamine, a synthetic catecholamine with predominantly b 1 -adrenergic properties, may reverse the terlipressin-associated depression in global oxygen supply in patients with catecholamine-dependent septic shock. Therefore, the primary endpoint of this prospective, randomized, controlled, open-labelled, clinical pilot study was to determine, whether dobutamine is a useful inotropic agent to reverse the reduction in Sv O 2 resulting from terlipressin bolus infusion. Secondary endpoints included differences in norepinephrine requirements, systemic and regional haemodynamics, and organ function between the groups.
Methods

Patients
The study was performed in an 18-bed multidisciplinary intensive care unit. It was approved by the local institutional ethics committee, and informed consent was obtained from the patients' next of kin. We enrolled patients who fulfilled the criteria of catecholaminedependent septic shock.
14 Enrolment of the patients started in November 2005 and ended in October 2006. All patients eligible for the study were included when the norepinephrine dose required to maintain mean arterial pressure (MAP) between 70 (5) mm Hg reached 0.9 mg kg 21 min
21
, despite adequate volume resuscitation [ pulmonary artery occlusion pressure (PAOP)¼12-15 mm Hg and central venous pressure (CVP)¼8 -12 mm Hg]. Exclusion criteria were age ,18 yr, pronounced cardiac dysfunction (i.e. CI2.2 litre min 21 m 22 in the presence of PAOP.18 mm Hg, significant valvular heart disease, present or suspected coronary artery disease), pregnancy, present or suspected acute mesenteric ischaemia or vasospastic diathesis (e.g. Raynaud's syndrome or related diseases).
From 180 screened septic patients, 70 consecutive patients met the inclusion criteria. Among these, 10 patients were excluded before randomization because of low CI (i.e. 2.2 litre min 21 m 22 in the presence of PAOP.18 mm Hg). The remaining 60 patients were enrolled in the present study.
All patients received mechanical ventilation using a volume-controlled mode. The ventilatory settings remained unchanged throughout the study. All patients were sedated with sufentanil and midazolam.
Measurements
Systemic haemodynamic monitoring of the patients included a pulmonary artery catheter (7.5 F, Edwards Lifesciences, Irvine, CA, USA) and a radial artery catheter. MAP, right atrial pressure (RAP), mean pulmonary arterial pressure (MPAP), and PAOP were measured at end-expiration. HR was analysed from a continuous recording of ECG with ST segments monitored. CI was measured using the continuous thermodilution technique (Vigilance II w , Edwards Lifesciences). Arterial and mixed venous blood samples were taken to determine oxygen tensions and saturations, carbon dioxide tensions, standard bicarbonate, and base excess (BE). Sv O 2 was measured discontinuously by intermittent mixed-venous blood gas analyses. Systemic vascular resistance index (SVRI), pulmonary vascular resistance index (PVRI), left-ventricular stroke work index (LVSWI), right-ventricular stroke work index (RVSWI), DO 2 I, oxygen consumption index (VO 2 I), and oxygen extraction ratio (O 2 -ER) were calculated using standard formulae.
Regional haemodynamic monitoring of the patients was performed using a 4 F oximetry thermo-dye dilution catheter (PV2024L, Pulsion Medical System AG, Munich, Germany) inserted through the femoral artery for the determinations of plasma disappearance rate of indocyanine green (PDR) and blood clearance of indocyanine green related to body surface area (CBI). PDR and CBI were determined with the Cold Z-021 system (Pulsion Medical System AG) using an established protocol. 15 16 In addition, an air-tonometer (Tonocap, Datex-Ohmeda, Helsinki, Finland) was inserted via the naso-gastric route for gastric mucosal carbon dioxide tension measurement and for the calculation of the gradient between gastric mucosal and arterial PCO 2 (Pg-a CO 2 ) .
Arterial blood samples were drawn and analysed for pH, arterial lactate, aspartate aminotransferase (ASAT), alanine aminotransferase (ALAT), total bilirubin (BILT), international normalized ratio (INR), activated partial thromboplastin time ratio (aPTTr), and cardiac troponin I (cTnI). Urine samples were collected to assess urinary output.
Study design
Sixty septic shock patients requiring norepinephrine doses of 0.9 mg kg 21 min 21 to maintain MAP at 70 (5) mm Hg, despite adequate volume resuscitation, were randomized to one of the three study groups (n¼20 each) using a computer-based procedure. In the 'control group' (Group 1), norepinephrine infusion was titrated to maintain the defined threshold MAP of 70 (5) . In all patients treated with terlipressin, norepinephrine was titrated to maintain MAP at 70 (5) mm Hg. All other medications were held constant.
Systemic, pulmonary, and regional haemodynamic measurements, and blood gases, were determined at baseline, and 2 and 4 h after randomization.
Surrogate variables of organ (dys)function and injury (ASAT, ALAT, BILT, INR, aPTTr, and cTnI) were analysed at baseline, and 12 and 24 h after randomization. Likewise, arterial lactate concentrations and urinary output were determined at baseline, and 2 and 4 h after randomization.
In patients surviving the 4 h intervention period, norepinephrine was titrated to maintain MAP at 70 (5) mm Hg. Dobutamine infusion was adjusted to keep Sv O 2 at baseline. None of the patients received further terlipressin infusions.
Statistical analysis
Sigma Stat 3.10 software (SPSS, Chicago, IL, USA) was used for statistical analysis. On the basis of a power analysis (expected standard deviation of residuals¼15%, desired power¼80%, and an alpha error¼5%), we determined that a sample size of n¼20 per group would be sufficient to detect a 15% decrease in Sv O 2 in the TP group. After testing for normal distribution (Kolmogorov -Smirnov test), differences within and between the groups were analysed using a two-way analysis of variance for repeated measurements. After confirming significant group differences over time, appropriate post hoc comparisons (Student -Newman -Keuls) were performed. The number of patients requiring norepinephrine infusion in each study group was compared using Fisher's exact test. For all statistical tests, a P-value of ,0.05 was regarded as statistically significant. Data are expressed as means (SD), if not otherwise indicated. 
Results
Each of the 60 patients enrolled into the present study completed the entire study period. One patient randomized to Group 2, however, had to be excluded from data analysis due to inappropriate weaning from norepinephrine (i.e. norepinephrine infusion rate had not been adequately reduced, although MAP levels exceeded goal values).
Demographic data
Baseline characteristics and causes of septic shock of the 59 patients analysed in the present study are summarized in Tables 1 and 2 , respectively. There were no differences in age, sex, body weight, Simplified Acute Physiology Score II (SAPS II), or time of norepinephrine infusion between the groups before randomization. All patients received i.v. hydrocortisone (200 mg day 21 continuously administered via an infusion pump). Five patients in Group 1, and four patients in Groups 2 and 3 received activated protein C during the study period. All patients included in the study survived the 4 h (haemodynamic) and 24 h (laboratory) study period. Overall mortality was not significantly different between the three study groups.
Systemic haemodynamic variables
There were no differences in haemodynamic variables and norepinephrine doses between the groups at baseline. When compared with Groups 1 and 3, CI was significantly lower in Group 2 at 2 h (P¼0.031 and P¼0.002, respectively; Fig. 2 ). Whereas the highest MAP was noticed in Group 3 (P0.001 between Group 1 and Group 2), the highest SVRI was recorded in patients allocated to Group 2 (P0.001 between Group 1 and Group 3; Fig. 2 ). In addition, LVSWI was higher in Group 3 than in the two other study groups (P¼0.006 between Group 1 and P¼0.013 vs Group 2; Fig. 2 ). In patients allocated to Group 2, RVSWI significantly decreased (P,0.001 compared with baseline at 2 h; Table 3 ). Despite a time-dependent decrease in HR in Group 2, HR was similar between the groups. Besides a significantly higher PVRI in Group 3 when compared with Group 2 (P¼0.047), MPAP, PAOP, and RAP remained unchanged during the intervention period (each P.0.05; Table 3 ).
Oxygen transport, gas exchange, and acid -base balance There were no differences in oxygen transport variables and acid -base balance between the groups at BL ( Fig. 3 ; Table 4 ). Whereas single terlipressin infusion reduced DO 2 I (P¼0.031 between Group 1 and P¼0.009 vs Group 3 at 2 h; Fig. 3 ) and increased O 2 -ER (P¼0.004 between Group 1 and P¼0.003 vs Group 3 at 2 h; Fig. 3 ), VO 2 I remained unchanged (Table 4) . When compared with Groups 1 and 3, Sv O 2 was significantly reduced in patients treated with sole terlipressin infusion (P¼0.034 between Group 1 and P¼0.039 vs Group 3 at 2 h after randomization; Fig. 3 ). There were no differences in pH, Pa CO 2 , Pa O 2 , Sa O 2 , BE, and Hb concentrations between the groups (each P.0.05; Table 4 ).
Regional haemodynamic variables and organ function
All investigated surrogate markers of organ (dys)function were similar between the groups at BL. During the intervention period, there was no difference in mucosal and regional blood flow variables (Pg-a CO 2 , PDR, and CBI). In addition, surrogate parameters of hepatic function and injury (BILT, ASAT, and ALAT), coagulation system (INR and aPTTr), and myocardial injury (cTnI) were similar between the groups (Table 5 ). However, terlipressin (with and without additional dobutamine infusion) increased urinary output when compared with baseline values (P,0.001 in Group 2 and P¼0.028 in Group 3 at 4 h; Table 5 ). Arterial lactate significantly increased over time in the control group (P¼0.008) and tended to increase when compared with the terlipressin group (P¼0.084 at 4 h after randomization; Fig. 3 ). 
Norepinephrine and dobutamine requirements
Whereas norepinephrine requirements increased over time in the control group, norepinephrine doses significantly decreased in Groups 2 and 3 (each P,0.001; Fig. 4 ). In eight patients in Group 2 and nine patients in Group 3, respectively, norepinephrine was discontinued after terlipressin administration (Table 6 ). Apart from temporary changes in skin colour (i.e. pallor) related to cutaneous vasoconstriction after terlipressin injection, we did not notice any skin lesions in the study population. Patients allocated to Group 3 required a mean dobutamine dose of 20 (8) 
Discussion
The major findings of the present study are (i) that terlipressin with and without additional dobutamine infusion markedly increased MAP and reduced norepinephrine requirements and (ii) that high dobutamine doses were needed to reverse the terlipressin-associated depression in Sv O 2 .
In accordance with previous clinical studies, 8 -11 terlipressin was effective in increasing MAP and allowed significant weaning from norepinephrine. Since we administered a relatively high bolus dose of terlipressin (1 mg), MAP exceeded goal values of 70 (5) mm Hg in some patients, despite discontinuation of norepinephrine infusion. In this regard, it is important to underline that in eight patients in Group 2 and in nine patients in Group 3, norepinephrine was completely discontinued after terlipressin administration (Table 6) .
Compared with the control group, however, terlipressin bolus infusion was linked to significant reductions in CI, DO 2 I, and Sv O 2 . The depression in CI is a typical characteristic of terlipressin bolus infusion 8 -11 17 and may be explained by baroreceptor activation and an increase in left ventricular afterload. 18 Alternatively, the terlipressinassociated reductions in CI and DO 2 I may also be explained by a reduction of global oxygen demand or myocardial dysfunction in response to an increased afterload. Recently, Broking and colleagues 19 reported that dobutamine is a useful agent to reverse the terlipressinassociated suppressions in CI and global oxygen transport in ovine endotoxaemia. However, the efficacy and safety of a combination therapy with terlipressin and dobutamine have not yet been determined in human septic shock.
Dobutamine is a synthetic catecholamine with b 1 -and b 2 -adrenergic properties. As a result of its positive inotropic and chronotropic effects, dobutamine increases HR and CI. In the present study, the combination of terlipressin and dobutamine maintained MAP at threshold values and reduced norepinephrine requirements. Notably, dobutamine increased CI, DO 2 I, and Sv O 2 without increasing HR. Since maintenance of adequate CI and Sv O 2 appears to be beneficial in septic shock, 20 the addition of dobutamine may be rational if terlipressin infusion alone leads to a reduction in Sv O 2 . However, it is still debated whether or not an increase in CI and DO 2 I represents a therapeutically useful goal. 20 21 The strong vasoconstrictive response after terlipressin bolus infusion necessitated high incremental dobutamine doses to reverse the depression in global oxygen transport. Nevertheless, it has to be taken into consideration that whereas dobutamine at 5 mg kg 21 min 21 is usually efficacious in normal subjects or in patients with non-septic heart failure, 22 23 it may be of poor efficacy in patients with severe septic shock because of impaired signal transduction and down-regulation of b-adrenergic receptors. 24 25 However, it is worth mentioning that despite the high dobutamine doses infused in the present study, no adverse events were noticed, even in those patients who required dobutamine dosages exceeding 20 mg kg 21 min
21
. In this regard, it may be especially important that there was no increase in HR in patients treated with high dobutamine doses and that troponin I concentrations were comparable between the groups (Table 7) . Although dobutamine infusion was adjusted to maintain Sv O 2 at baseline, Sv O 2 values were higher at the end of the intervention period. This may be explained by discontinuous measurements of this variable and the short intervention period that made it difficult to exactly adjust the dobutamine dose to re-establish baseline Sv O 2 values.
Previous studies using vasopressin receptor agonists in patients with septic shock after adequate fluid resuscitation showed less or no unwanted side-effects in the splanchnic circulation. 6 9 26 27 In harmony with these findings, terlipressin did not increase the Pg-a CO 2 gap in the present study. Whereas dobutamine prevented the terlipressinassociated impairments in CI and DO 2 I, we did not notice differences between the three study groups in terms of Pg-a CO 2 gap. The absence of detrimental splanchnic haemodynamic effects is also confirmed by the lack of differences between the groups in PDR and CBI. On the contrary, the absence of significant increases in arterial lactate concentrations (when compared with the control group) suggests a positive effect on oxygen balance and tissue oxygenation in both terlipressin-treated groups. However, since lactate generation during septic shock may be fostered by catecholamines, 28 the difference between the terlipressin-treated groups and the control group may have also been related to decreased norepinephrine requirements.
Our results are in accordance with the recent study of Asfar and colleagues. 27 The latter authors reported that although terlipressin decreased both cardiac output and portal venous blood flow, it increased hepatic arterial blood flow, thereby leading to an unaffected splanchnic oxygen delivery and Pg-a CO 2 gradient. In harmony with the results of the liver perfusion measurements (i.e. PDR and CBI), we did not find differences in terms of liver (5) 26 (5) 26 (5) Group 2 (n¼19) 26 (5) 25 (5) 27 (5) Group 3 (n¼20)
27 (5) 28 (5) 28 (5) PAOP (mm Hg) Group 1 (n¼20) 14 (2) 14 (2) 14 (2) Group 2 (n¼19) 14 (2) 15 (2) 15 (2) Group 3 (n¼20)
15 (2) 16 (2) 16 (2) RAP (mm Hg) Group 1 (n¼20) 12 (4) 12 (3) 12 (3) Group 2 (n¼19) 12 (2) 12 (2) 11 (3) Group 3 (n¼20)
11 (3) 12 (3) 12 ( (8) enzymes and BILT 24 h after terlipressin administration, suggesting a lack of drug-related acute hypoxic liver injury.
In line with previous clinical trials, 9 -11 urinary output increased over time in both terlipressin-treated groups, despite its potential antidiuretic effect. In this context, it is noteworthy that vasopressin analogues may increase glomerular filtration rate by increasing resistance of efferent glomerular arterioles without constricting afferent arterioles. 29 In addition, terlipressin is less likely to produce antidiuretic effects when compared with arginine vasopressin due to the higher V 1 receptor selectivity of terlipressin.
In the light of our results, we would like to emphasize that potential benefits of increasing Sv O 2 after terlipressin infusion need to be weighted against the potential risk of cardiovascular complications resulting from high dose dobutamine infusion. Future large-scale studies are needed to clarify whether the combination of terlipressin and dobutamine is superior to standard therapy with norepinephrine. It also remains to be determined whether the reductions in CI and Sv O 2 after terlipressin infusion have to be regarded as detrimental effects, or as a surrogate of reduced metabolic demands.
The present study has some limitations that need to be acknowledged. First, direct measurements of regional and local splanchnic blood flow in septic shock patients would be invasive, require special skills and instruments that are not readily available at the bedside. Thus, in the present study, hepatosplanchnic perfusion was assessed using PDR and CBI; mucosal blood flow was evaluated by gastric tonometry. Secondly, terlipressin was administered at a fixed dose without adaptation for body weight. However, body weight of the enrolled patients was similarly distributed within the three study groups. In addition, terlipressin was administered as a relatively high dose bolus infusion, which resulted in decreases in CI, DO 2 I, and Sv O 2 . A continuous, low-dose infusion of terlipressin may prevent these unwanted side-effects 30 31 and thus may reduce dobutamine requirements. Thirdly, since the effects of the combination therapy of terlipressin and dobutamine were not exactly predictable, for safety reasons the present trial was designed as a short-term haemodynamic pilot study. Therefore, we investigated only a small number of septic shock patients treated with a single dose of terlipressin to evaluate the effects of a titrated dobutamine infusion on cardiopulmonary haemodynamics and global oxygen transport over a brief period. Hence, we cannot rule out the possibility of adverse metabolic alterations or side-effects in response to repeated administration of terlipressin alone or in combination with dobutamine for a prolonged reported a positive correlation between high norepinephrine doses and mortality, it is still unclear whether the reduction of norepinephrine dosages per se represents a therapeutic target.
In conclusion, this is the first prospective, randomized clinical study showing that terlipressin bolus administration (with and without concomitant dobutamine infusion) significantly reduces norepinephrine requirements in septic shock patients and that high doses of dobutamine are needed to reverse the terlipressin-linked depression in Sv O 2 . In this context, it is noteworthy that dobutamine infusion in the present study was not associated with any clinically obvious cardiovascular side-effects. However, large-scale studies are needed to clarify whether combined terlipressin and dobutamine infusion improves the overall outcome when compared with norepinephrine infusion. In addition, future trials are warranted to investigate whether continuous low-dose terlipressin infusion, or intermittent infusion of low-dose terlipressin boli, may omit decreases in CI and Sv O 2 , 30 and thereby reduce inotropic requirements. Table 5 Regional haemodynamic variables of study patients. Data are presented as mean values (SD). TP, Group 2, terlipressin; Group 3, terlipressin and dobutamine; BL, baseline; Pg-a CO 2 , difference between gastric mucosal and arterial carbon dioxide partial pressure; CBI, blood clearance of indocyanine green; PDR, plasma disappearance rate of indocyanine green.
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